NextCure Inc Cash Flow Conversion Efficiency
NextCure Inc cash flow conversion efficiency. Based on the latest financial reports, NextCure Inc (NXTC) has a cash flow conversion efficiency ratio of -0.800x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.71 Million) by net assets ($12.15 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of NextCure Inc (2017–2025)
Cash flow conversion efficiency of NextCure Inc from 2017 to 2025. This chart illustrates how NextCure Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View NXTC share price today for real-time trading data and today's change.
NextCure Inc Cash Flow Conversion Ratio Explained
NextCure Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
NextCure Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NextCure Inc ranked by their cash flow conversion efficiency. Also see NextCure Inc (NXTC) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fancamp Exploration Ltd.
V:FNC
|
-0.024x |
|
Myungmoon Phar
KO:017180
|
0.005x |
|
Softing AG
XETRA:SYT
|
-0.060x |
|
Inalways
TWO:5398
|
0.012x |
|
Origin Materials Inc
NASDAQ:ORGN
|
-0.028x |
|
Maral Overseas Limited
NSE:MARALOVER
|
0.505x |
|
Pioneer Motor Public Company Limited
BK:PIMO
|
0.043x |
|
Senetas Corporation Ltd
AU:SEN
|
-0.024x |
Annual Cash Flow Conversion Efficiency for NextCure Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of NextCure Inc from 2017 to 2025. Review NextCure Inc (NXTC) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $34.94 Million | $-49.61 Million | -1.420x | -127.81% |
| 2024-12-31 | $65.47 Million | $-40.80 Million | -0.623x | -34.62% |
| 2023-12-31 | $114.42 Million | $-52.97 Million | -0.463x | -43.94% |
| 2022-12-31 | $167.53 Million | $-53.89 Million | -0.322x | -31.14% |
| 2021-12-31 | $233.39 Million | $-57.24 Million | -0.245x | -60.26% |
| 2020-12-31 | $293.72 Million | $-44.95 Million | -0.153x | -38.12% |
| 2019-12-31 | $321.48 Million | $-35.62 Million | -0.111x | +34.91% |
| 2018-12-31 | $-46.94 Million | $7.99 Million | -0.170x | -133.21% |
| 2017-12-31 | $-24.41 Million | $-12.51 Million | 0.513x | -- |
About NextCure Inc
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leuke… Read more